Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
7 Lisdexamphetamine (Vyvanse) is currently approved for binge-eating disorder in adults aged 18 years and older and in children aged 6 years and older diagnosed with attention-deficit/hyperactivity disorder, though its mechanism of action in treating both indications is still unclear
Third-party review ratings Independent review sites paint a more mixed picture than the company hosted reviews
3 Limitations of Use: Concomitant use in combination with any other product containing a GLP-1 receptor agonist is not recommended
Clinical research shows that significant weight loss often starts to become apparent within approximately 4 to 12 weeks
US$ 22.27
US$ 28.80
US$ 21.05
US$ 20.21
US$ 29.75
US$ 28.88
US$ 29.78
